ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

XENE Xenon Pharmaceuticals Inc

38.91
-0.35 (-0.89%)
15 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Xenon Pharmaceuticals Inc NASDAQ:XENE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.35 -0.89% 38.91 38.45 40.35 39.84 38.46 39.34 410,263 01:00:00

Xenon to Report Q3 2024 Financial Results on November 12, 2024

05/11/2024 9:01pm

GlobeNewswire Inc.


Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart


From Aug 2024 to Feb 2025

Click Here for more Xenon Pharmaceuticals Charts.

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024.

Conference Call/Webcast Information:

Date: Tuesday, November 12, 2024
  
Time:4:30 pm Eastern Time (1:30 pm Pacific Time)
  
Webcast: Pre-register here 
  
Dial-In:  (800) 715-9871 toll-free or (646) 307-1963 for international callers
  
Conference ID:7128308

A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts: For Investors:Chad FugereVice President, Investor Relations(857) 675-7275investors@xenon-pharma.com

For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@xenon-pharma.com

1 Year Xenon Pharmaceuticals Chart

1 Year Xenon Pharmaceuticals Chart

1 Month Xenon Pharmaceuticals Chart

1 Month Xenon Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock